Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis

Accepted/In Press date: 17 April 2022

e-pub ahead of print date: 20 April 2022

Published date: September 2022

Additional Information: Funding Information: This review was conducted as part of the development of food allergy guidelines for GA2LEN, where contributors volunteered their time. This research was part-funded by the UK Medical Research Council (grant references MR/K010468/1 and MR/W018616/1) to PJT. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed in this article are those of the author(s) and do not necessarily reflect those of the NHS, NIHR, or the UK Departments of Health Funding Information: Dr Turner reports personal fees from Aimmune Therapeutics, DBV Technologies, Allergenis, UK Food Standards Agency and ILSI Europe; grants from National Institute for Health Research (NIHR)/Imperial Biomedical Research Centre, UK Medical Research Council, UK Food Standards Agency, End Allergies Together, Jon Moulton Charity Trust, outside the submitted work. Prof Halken reports speaker/chair fees from Nestlé Purina and ABIGO Pharma A/S. Dr Muraro reports speaker fees from Aimmune Therapeutics, DBV, and Nestlé Purina; and is an advisory board member/fees from Regeneron IDMC. Dr Deschildre reports personal fees from ALK, Stallergènes‐Greer, GSK, Novartis, Sanofi, Regeneron, Bohringer Ingelheim, Aimmune therapeutics, DBV technologies, Nestlé Health Science, Nutricia, outside the submitted work. Dr Ballmer‐Weber reports personal fees from ALK, Allergopharma, ThermoFisher, Menarini, Sanofi, Novartis. Prof. van Ree reports personal fees from HAL Allergy, ALK, Citeq, Angany, ThermoFisher, Reacta Healthcare, and Mission MightyMe; grants from European Commission, Dutch Science Foundation, and Health Holland, outside the submitted work. Prof. Worm declares the receipt of honoraria or consultation fees by the following companies: ALK‐Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi‐Aventis Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Allergopharma GmbH & Co.KG, Bencard Allergie GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG., AbbVie Deutschland GmbH & Co. KG and Lilly Deutschland GmbH, outside the submitted work. Prof Zuberbier reports personal fees from Bayer, FAES, Novartis, Henkel, AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bencard, Berlin Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan, L’Oréal, outside the submitted work. Prof Roberts reports grants from UK Food Standards Agency, DBV and the European Union. The other authors have no relevant conflicts of interest to declare. Funding Information: This review was conducted as part of the development of food allergy guidelines for GALEN, where contributors volunteered their time. This research was part‐funded by the UK Medical Research Council (grant references MR/K010468/1 and MR/W018616/1) to PJT. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed in this article are those of the author(s) and do not necessarily reflect those of the NHS, NIHR, or the UK Departments of Health 2 Publisher Copyright: © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Keywords: anaphylaxis, biomarkers, food allergy, risk assessment, severity

Local EPrints ID: 457159

URI: http://eprints.soton.ac.uk/id/eprint/457159

DOI: doi:10.1111/all.15318

ISSN: 0105-4538

PURE UUID: 017b2f0c-f20b-41da-b480-99c57bc6ef11

ORCID for Graham Roberts: orcid.org/0000-0003-2252-1248

Date deposited: 25 May 2022 16:40

Last modified: 17 Mar 2024 03:02